Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela M Minassian

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Cell|July 26, 2024
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5Lawrence T Wang, Andrew J R Cooper, Brendan Farrell, et al.
Epidemiology and Infection|January 22, 2024
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insightOlivia Bird, Eva P Galiza, David Neil Baxter, et al.
Med (New York, N.Y.)|August 12, 2023
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adultsSarah E Silk, Wilmina F Kalinga, Ivanny M Mtaka, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Science Translational Medicine|July 12, 2023
Vaccination with <i>Plasmodium vivax</i> Duffy-binding protein inhibits parasite growth during controlled human malaria infectionMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
Medrxiv : the Preprint Server for Health Sciences|June 6, 2022
Impact of a blood-stage vaccine on <i>Plasmodium vivax</i> malariaMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
Cell Reports. Medicine|July 17, 2024
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodiesLloyd D W King, David Pulido, Jordan R Barrett, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Nature Medicine|December 18, 2020
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Cell|July 26, 2024
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5Lawrence T Wang, Andrew J R Cooper, Brendan Farrell, et al.
Epidemiology and Infection|January 22, 2024
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insightOlivia Bird, Eva P Galiza, David Neil Baxter, et al.
Med (New York, N.Y.)|August 12, 2023
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adultsSarah E Silk, Wilmina F Kalinga, Ivanny M Mtaka, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Science Translational Medicine|July 12, 2023
Vaccination with <i>Plasmodium vivax</i> Duffy-binding protein inhibits parasite growth during controlled human malaria infectionMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
Medrxiv : the Preprint Server for Health Sciences|June 6, 2022
Impact of a blood-stage vaccine on <i>Plasmodium vivax</i> malariaMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.
Cell Reports. Medicine|July 17, 2024
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodiesLloyd D W King, David Pulido, Jordan R Barrett, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Nature Medicine|December 18, 2020
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Pageof 7